Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page
- CheckyesterdayChange DetectedNew revision entry v3.3.4 was added and the previous revision v3.3.3 was removed in the Record History. This appears to be a routine system update to the page rather than a change to study information.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedFooter metadata updated to Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedFooter revision label updated from v3.2.0 to v3.3.2. The update appears limited to site version display and does not affect study data or functionality.SummaryDifference0.0%

- Check58 days agoChange DetectedRemoved the government funding/status notice banner from the page, a non-core site-wide element that does not alter the study record, data, or user navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check73 days agoChange DetectedRecord History now displays additional version entries with updated timestamps, while core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check102 days agoChange DetectedMajor update: page now includes a government funding lapse notice and confirms the NIH Clinical Center is open, with status sources listed, and a version upgrade to v3.2.0.SummaryDifference8%

Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.